What we're reading, June 14, 2016: CMS has proposed requiring Medicare hospitals follow new antibiotic controls; New York poised to expand access to breast cancer screening; and clinical trials are seeing more success.
CMS has proposed that Medicare hospitals closely manage the use of antibiotics or be ejected from the program. According to The Wall Street Journal, CMS would require that hospitals adopt new antibiotic controls in an attempt to reduce overuse. Federal health officials are concerned about the growing threat of antibiotic resistant bacteria. Under the proposal, hospitals would have someone in charge of antibiotic oversight.
New York is looking to increase access to breast cancer screening under a new deal by lawmakers. Hospitals would be required to expand hours when mammograms are offered and insurers would have to eliminate deductibles and copays for some diagnostic tests, including screening, reported the AP. The measure is expected to pass with the support of Governor Andrew Cuomo, the Democratic assembly speaker, and the Republican senate leader.
Clinical trials are reporting greater success rates. STAT reported that more than 11% of clinical trials succeeded between 2012 and 2014, which reversed the downward trend of the last 2 decades. The declines in clinical trial success rates was attributed to many drug makers cutting back on R&D. The success rate had bottomed out at 7.5% between 2008 and 2011, which was far below the 16.4% success rate seen between 1996 and 1999.
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More